Clinical trials: Brachytherapy
NSCLC, Non Small Cell Lung Cancer
A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer
For patients diagnosed with early (Stage I) non-small cell lung cancer, a lobe of lung is usually removed at surgery to treat the cancer.
- Trial name
- NCT01237171
- Testing
- Cesium-131 Brachytherapy Seed
- Where
- United States
- Sponsor
- IsoRay Medical, Inc.
Basal Cell Carcinoma, Squamous Cell Carcinoma of the Skin
CivaDerm(TM) Surface Therapy Pilot Study
This is a pilot study to determine the usefulness of new brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit basal cell and squamous cell carcinoma…
- Trial name
- NCT04480645
- Testing
- CivaDerm
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- CivaTech Oncology
Unresectable Locally Advanced Pancreatic Carcinoma
A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine+Abraxane
To evaluate the safety of OncoSil™ in a patient population undergoing standard chemotherapy treatment for pancreatic cancer. This study has been designed to satisfy regulatory requirements.
- Trial name
- PanCO (NCT03003078)
- Testing
- OncoSil™
- Where
- 12 sites in Australia, Belgium and 1 more
- Volunteers
- 50 people
- Sponsor
- OncoSil Medical Limited
Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer
- Conditions
- Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy, Prostate Cancer Recurrent, Prostate Cancer Patients Who Have Brachytherapy Seed Implant
- Trial name
- AMPLIFY (NCT06970847)
- Testing
- 64Cu-SAR-bisPSMA
- Where
- 22 sites in United States, Australia
- Volunteers
- 220 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Uveal Melanoma
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
- Trial name
- NCT05907954
- Testing
- Darovasertib
- Where
- 18 sites in United States, Australia and 5 more
- Volunteers
- 160 people
- Sponsor
- IDEAYA Biosciences
Recurrent Glioblastoma, Recurrent Gliomas
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of recurrent Glioblastoma
- Trial name
- NCT06910306
- Testing
- Device :DaRT seeds
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Alpha Tau Medical LTD.
Recurrent Squamous Cell Carcinoma
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma
This is a multi-center clinical study enrolling up to 86 participants. The primary objectives are to determine the objective response rate (ORR) established by the confirmed best overall response (BOR) following intratumoral…
- Trial name
- NCT05323253
- Testing
- DaRT seeds
- Where
- 28 sites in United States, Canada and 1 more
- Volunteers
- 86 people
- Sponsor
- Alpha Tau Medical LTD.
Age-Related Macular Degeneration, Polypoid Choroidal Vasculopathy
Adjunct Episcleral Brachytherapy for PCV
This study is investigating the use of episcleral brachytherapy (ESB) adjunct to aflibercept compared to aflibercept monotherapy for the treatment of polyploid choroidal vasculopathy (PCV) in patients experiencing an inadequate…
- Trial name
- KILAUEA (NCT05251636)
- Testing
- Episcleral Brachytherapy, Aflibercept Injection
- Volunteers
- 159 people
- Sponsor
- Salutaris Medical Devices, Inc.
Macular Degeneration, Choroidal Neovascularization
Episcleral Brachytherapy for the Treatment of Wet AMD
This is a prospective, multi-site, safety and feasibility study of the SalutarisMD SMD-DA system for retrobulbar minimally invasive episcleral brachytherapy device in patients receiving and not responding to anti-VEGF therapy for…
- Trial name
- NEAMES (NCT02988895)
- Testing
- episcleral brachytherapy
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Salutaris Medical Devices, Inc.
Age Related Macular Degeneration
A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal CNV Associated With Wet AMD in Patients That Require Persistent Anti-VEGF Therapy
The objective of the MERITAGE Trial is to evaluate the safety and efficacy of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) associated with wet age-related macular degeneration…
- Trial name
- MERITAGE (NCT00809419)
- Testing
- NeoVista Ophthalmic System
- Where
- 5 sites in United States, Israel and 1 more
- Volunteers
- 32 people
- Sponsor
- NeoVista
Basal Cell Carcinoma, Squamous Cell Carcinoma
Electronic Brachytherapy for the Treatment of NMSC
The objective of this study is to record recurrence in patients treated for nonmelanoma (basal cell and squamous cell carcinomas) skin cancer using the Xoft Axxent Electronic Brachytherapy System.
- Trial name
- NCT01016899
- Testing
- electronic brachytherapy
- Where
- 5 sites in United States
- Volunteers
- 187 people
- Sponsor
- Xoft, Inc.
Breast Neoplasms
A Registry Study of Breast Microseed Treatment
For women diagnosed with early stage breast cancer, lumpectomy followed by radiation is a common treatment option. Radiation treatment is typically delivered to the whole breast, five times per week, for anywhere from 3 to 8…
- Trial name
- NCT02701244
- Testing
- Permanent Breast Seed Implant (PBSI)
- Where
- 3 sites in United States
- Volunteers
- 420 people
- Sponsor
- Concure Oncology-Breast Microseed Inc.
Liver, Cancer of, Non-Resectable
QuiremSpheres Observational Study
The main purpose of this study is to further assess treatment efficacy and safety after using QuiremSpheres® for the treatment of patients with unresectable primary liver cancer or unresectable liver metastases suitable for SIRT…
- Trial name
- Hope166 (NCT03563274)
- Testing
- Selective Internal Radiation Therapy with QuiremSpheres®
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 20 people
- Sponsor
- Terumo Europe N.V.
Prostate Cancer
NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma
This study is a Phase 1/2 open-label involving 2 groups of patients newly diagnosed with either unfavorable intermediate risk or high risk prostate adenocarcinoma.
- Trial name
- NCT02805894
- Testing
- NBTXR3 activated by IMRT only, NBTXR3 activated by Brachytherapy & IMRT
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Nanobiotix
Prostate Cancer
Observation of Outcomes and Side Effects of Cesium-131 in Combination With External Beam Radiation for the Treatment of Intermediate to High Risk Prostate Cancer
The purpose of this study is to observe PSA response and incidence of side effects in patients diagnosed with intermediate to high risk prostate cancer and treated with Cesium-131 in combination of external beam therapy.
- Trial name
- NCT00621413
- Where
- 9 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- IsoRay Medical, Inc.
Unresectable Hepatocellular Carcinoma
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
The goal of this clinical trial is to evaluate the efficacy and safety of NRT6003 Injection compared to cTACE in patients with unresectable HCC.
- Trial name
- CHEERS (NCT06900543)
- Testing
- NRT6003 Injection, cTACE
- Where
- 19 sites in China
- Volunteers
- 108 people
- Sponsor
- Chengdu New Radiomedicine Technology Co. LTD.
Hepatocellular Carcinoma Non-resectable, Metastatic Colorectal Cancer
Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) and Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to evaluate the safety of treatment with Eye90 microspheres in patients with unresectable Hepatocellular Carcinoma (HCC) and metastatic Colorectal Cancer (mCRC).
- Conditions
- Hepatocellular Carcinoma Non-resectable, Metastatic Colorectal Cancer, Liver Cancer
- Trial name
- NCT04926376
- Testing
- Eye90 Microspheres
- Where
- New Zealand
- Volunteers
- 8 people
- Sponsor
- ABK Biomedical
Cervical Cancer
Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer
The purpose of this study is to evaluate the safety, performance and usability of the Xoft Axxent Electronic Brachytherapy System and Cervical Applicator as incorporated into the physician's current standard treatment practice…
- Trial name
- NCT01851772
- Testing
- Treatment with Electronic Brachytherapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Xoft, Inc.
Head and Neck Squamous Cell Carcinoma, Skin Cancer
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC
A unique combinational treatment for cancer employing intratumoral diffusing alpha radiation emitter device with check point inhibitor for recurrent unresectable or metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma
- Trial name
- NCT05047094
- Testing
- Diffusing Alpha Radiation Emitters Therapy (DaRT), Pembrolizumab
- Where
- 3 sites in Israel
- Volunteers
- 48 people
- Sponsor
- Alpha Tau Medical LTD.
Pancreas Cancer, Cancer
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
This is a Phase I evaluation to determine the usefulness of a new brachytherapy device that utilizes active components (Palladium-103) of standard devices in a novel configuration.
- Trial name
- NCT03109041
- Testing
- CivaSheet
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- CivaTech Oncology